Remove Drug Development Remove Pharma Companies Remove Pharmaceutical Companies Remove Small Molecule
article thumbnail

Where is the drug discovery expertise happening in the UK?

Drug Discovery World

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. Cambridge is a focal point for many pharmaceutical companies working in this therapeutic area.

Drugs 189
article thumbnail

Synthetic biology tools advancing and accelerating drug discovery efforts

Drug Discovery World

If a pharmaceutical company is racing to identify a new vaccine, for instance, then waiting for three weeks to receive DNA sequences each time can slow down the development process compared to competitors who might have faster timelines.” . Synthetic libraries for antibody drug discovery .

DNA 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What to expect from drug discovery and development in 2023

Drug Discovery World

However, coming off the back of high levels of return on investment (ROI) seen throughout Covid-19 and therefore 2021, was always going to be difficult for the pharma industry. As such, 2022 saw a marked fall in ROI for global pharmaceutical companies and their research and development activities.

article thumbnail

Algae: a source for prebiotics and drugs to treat IBD

Drug Target Review

Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.

Drugs 75
article thumbnail

AI At The Frontier: Empowering Early Career Professionals In Drug Discovery

Elrig

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. There, I supported AI-enabled DD efforts in their small molecule portfolio. big pharma or startups/spin off? What pro/cons?